GMDA Gamida Cell Ltd.

4.58
+0.04  (+1%)
Previous Close 4.54
Open 4.65
Price To Book 3.16
Market Cap 154,196,353
Shares 33,667,326
Volume 12,209
Short Ratio
Av. Daily Volume 38,307
Stock charts supplied by TradingView

NewsSee all news

  1. Gamida Cell Announces 2020 Goals and Provides Company Update

    – Topline data from Phase 3 study of omidubicel expected in first half of 2020 – – GDA-201 program progressing with additional data expected in first half of 2020 – – Jas Uppal, Ph.D., appointed as chief regulatory

  2. Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel

    – Topline data expected in first half of 2020 – Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced that in December the

  3. Gamida Cell Announces Results from Phase 1 Study of GDA-201 and New Mechanism of Action Data at ASH 2019 Annual Meeting

    — GDA-201 demonstrated early evidence of clinical activity in patients with non-Hodgkin lymphoma, with multiple complete responses observed — — Research on mechanism of action for the NAM technology platform provides

  4. Gamida Cell to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph.D., the company's chief executive officer,

  5. Gamida Cell Reports Third Quarter 2019 Financial Results and Provides Company Update

    – Completion of patient enrollment in Phase 3 clinical study of omidubicel expected by year-end; Topline data anticipated in first half of 2020 – – Additional results from Phase 1 study of GDA-201 and new data on NAM

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data at ASH December 9, 2019. NHL ORR 67%. Additional data due 1H 2020.
NAM-NK (GDA-201)
Non-Hodgkin lymphoma; Multiple myeloma
Phase 1/2 enrolment of second cohort commenced June 2019.
NiCord (omidubicel)
Severe aplastic anemia
Phase 3 completion of enrolment announced December 2, 2019 with top-line data due 1H 2020.
NiCord (omidubicel)
Acute myeloid leukemia

Latest News

  1. Gamida Cell Announces 2020 Goals and Provides Company Update

    – Topline data from Phase 3 study of omidubicel expected in first half of 2020 – – GDA-201 program progressing with additional data expected in first half of 2020 – – Jas Uppal, Ph.D., appointed as chief regulatory

  2. Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel

    – Topline data expected in first half of 2020 – Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced that in December the

  3. Gamida Cell Announces Results from Phase 1 Study of GDA-201 and New Mechanism of Action Data at ASH 2019 Annual Meeting

    — GDA-201 demonstrated early evidence of clinical activity in patients with non-Hodgkin lymphoma, with multiple complete responses observed — — Research on mechanism of action for the NAM technology platform provides

  4. Gamida Cell to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Gamida Cell Ltd. (NASDAQ:GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph.D., the company's chief executive officer,

  5. Gamida Cell Reports Third Quarter 2019 Financial Results and Provides Company Update

    – Completion of patient enrollment in Phase 3 clinical study of omidubicel expected by year-end; Topline data anticipated in first half of 2020 – – Additional results from Phase 1 study of GDA-201 and new data on NAM

  6. Gamida Cell Announces Data to be Presented at ASH 2019 Annual Meeting

    – Presentations to include updated results from Phase 1 study of GDA-201 and new data on mechanism of action for NAM cell expansion platform – Gamida Cell Ltd. (NASDAQ:GMDA), a leading cellular and immune therapeutics

  7. Gamida Cell Announces the Date of Its Third Quarter 2019 Financial Results and Webcast

    Gamida Cell Ltd. (NASDAQ:GMDA), a leading cellular and immune therapeutics company, today announced that the company will host a conference call and live audio webcast on Wednesday, November 13, 2019, at 4:30 p.m. ET to

  8. Gamida Cell and the CIBMTR Announce Collaboration to Advance Research for Life-Saving Cellular Therapy

    – Multi-Year Observational Study Designed to Evaluate Outcomes of Patients with Hematologic Malignancies Who Undergo Allogeneic Bone Marrow Transplantation – Gamida Cell Ltd. (NASDAQ:GMDA), a leading cellular and